Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25324757 | 0.88 | F11 (0.59) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL25324861 | 0.88 | F11 (0.61) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL25326106 | 0.87 | F11 (0.58) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL25329102 | 0.87 | F11 (0.58) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL25328209 | 0.85 | KDM4E (0.56) | F11SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL25326098 | 0.84 | F11 (0.55) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL29565288 | 0.84 | F11 (1.00) | F11ALDH1A1XDH | |
| SCHEMBL25326934 | 0.84 | F11 (1.00) | F11ALDH1A1XDH | |
| SCHEMBL25328067 | 0.84 | F11 (0.54) | F11GRM5TLR8TLR7SMN1; SMN2 | |
| SCHEMBL25326084 | 0.84 | F11 (0.56) | F11GRM5TLR8TLR7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105881-B | Platelet aggregation inhibitor, and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | claimed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | claimed |
| CN-114105881-B | Platelet aggregation inhibitor, and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| CN-114105881-A | Platelet aggregation inhibitor and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | TFPI, F12, TFPI2 | F11 7/4885GRM5 4442/4885TLR8 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.